{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:41Z","timestamp":1787026961000,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    In melanoma and other malignancies, low vitamin D status is associated with increased risk and poor prognosis. However, there are limited data of the impact of 25(OH)D serum concentration (s.c.) on clinical outcome in advanced melanoma. We tested the hypothesis that vitamin D status is predictive of efficacy and safety in patients treated for metastasized melanoma with B-rapidly accelerated fibrosarcoma (BRAF), mitogen-activated protein kinase kinase (MEK), cytotoxic T lymphocyte-associated protein-4 (CTLA-4), and\/or programmed cell death protein-1 (PD-1) inhibitors. Severe vitamin D deficiency [defined as 25(OH)D s.c. &amp;lt;10 ng\/ml] was associated with markedly reduced overall (OS) and progress-free (PFS) survival, with increased tumor load [TL; measured as s.c. of S100 protein or lactate dehydrogenase (LDH)], and with a trend for higher frequency of adverse events (AEs). An increase in average 25(OH)D s.c. of 1 ng\/ml was associated with a 3.9% reduced risk for progressive disease [hazard ratio (HR) = 0.961,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.044], with a reduction of LDH s.c. of 3.86 U\/l (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.034, indicating a reduction of TL), and with a trend for reduced frequency of AEs (AE ratio -0.005;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.295). Patients with average 25(OH)D s.c. \u226510 ng\/ml and\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant melanoma showed a trend for a higher frequency of AEs as compared to individuals with\n                    <jats:italic>BRAF<\/jats:italic>\n                    wild-type melanomas. Our data indicate that vitamin D deficiency is associated with poor clinical outcome in patients treated for metastasized melanoma with BRAF\/MEK inhibitors or immunotherapy. Although it needs to be proven in future interventional trials whether optimizing serum 25(OH)D improves clinical outcome in these patients, we recommend that 25(OH)D s.c. should be analyzed and vitamin D deficiency treated in all patients with advanced melanoma.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2022.839816","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T16:41:11Z","timestamp":1653064871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Low Vitamin D Status Predicts Poor Clinical Outcome in Advanced Melanoma Treated With Immune Checkpoint or BRAF\/MEK Inhibitors: A Prospective Non-Interventional Side-by-Side Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"J\u00f6rg","family":"Reichrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Biersack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sch\u00f6pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Saternus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1001","article-title":"A Systematic Review and Network Meta-Analysis of Immunotherapy and Targeted Therapy for Advanced Melanoma","volume":"6","author":"da Silveira Nogueira Lima","year":"2017","journal-title":"Cancer Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111642","article-title":"Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma","volume":"11","author":"Hamid","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011123.pub2","article-title":"Systemic Treatments for Metastatic Cutaneous Melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic Therapy for Melanoma: ASCO Guideline [Published Online Ahead of Print, 2020 Mar 31]","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/bjd.18413","article-title":"Severe Vitamin D Deficiency Associated With BRAF-Mutated Melanoma","volume":"181","author":"Fearfield","year":"2019","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29334","article-title":"25-Hydroxyvitamin D2\/D3 Levels and Factors Associated With Systemic Inflammation and Melanoma Survival in the Leeds Melanoma Cohort","volume":"136","author":"Newton-Bishop","year":"2015","journal-title":"Int J Cancer"},{"key":"B7","article-title":"Reduced Serum 25-Hydroxyvitamin D Levels in Stage IV Melanoma Patients","volume":"29","author":"N\u00fcrnberg","year":"2009","journal-title":"Anticancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO","article-title":"Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma","volume":"27","author":"Newton-Bishop","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112863","article-title":"Low Serum 25-Hydroxyvitamin D Concentrations Are Associated With Increased Risk for Melanoma and Unfavourable Prognosis","volume":"9","author":"Bade","year":"2014","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4161\/cbt.6.1.3493","article-title":"In Vitro Comparison of the Vitamin D Endocrine System in 1,25(OH)2D3-Responsive and -Resistant Melanoma Cells","volume":"6","author":"Reichrath","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3927","article-title":"Vitamin D-VDR Signaling Inhibits Wnt\/\u03b2-Catenin-Mediated Melanoma Progression and Promotes Antitumor Immunity","volume":"79","author":"Muralidhar","year":"2019","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.05.016","article-title":"Vitamin D in Melanoma: Controversies and Potential Role in Combination With Immune Check-Point Inhibitors","volume":"69","author":"Stucci","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa3230","article-title":"Vitamin D-Dependent Induction of Cathelicidin in Human Macrophages Results in Cytotoxicity Against High-Grade B Cell Lymphoma","volume":"7","author":"Bruns","year":"2015","journal-title":"Sci Transl Med"},{"key":"B14","unstructured":"Guideline on Good Pharmacovigilance Practices (GVP) Module VIII \u2013 Post-Authorisation Safety Studies (Rev 3)2017"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-002","article-title":"Intraindividual Variation in Plasma 25-Hydroxyvitamin D Measures 5 Years Apart Among Postmenopausal Women","volume":"21","author":"Meng","year":"2012","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and Clarification: From the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2017.3","article-title":"Vitamin D Signaling and Melanoma: Role of Vitamin D and Its Receptors in Melanoma Progression and Management","volume":"97","author":"Slominski","year":"2017","journal-title":"Lab Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2017.06.013","article-title":"On the Role of Classical and Novel Forms of Vitamin D in Melanoma Progression and Management","volume":"177","author":"Slominski","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-020-00913-6","article-title":"Photoprotective Properties of Vitamin D and Lumisterol Hydroxyderivatives","volume":"78","author":"Slominski","year":"2020","journal-title":"Cell Biochem Biophys"},{"key":"B20","article-title":"Decreased VDR Expression in Cutaneous Melanomas as Marker of Tumor Progression: New Data and Analyses","volume":"34","author":"Bro\u017cyna","year":"2014","journal-title":"Anticancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14002","article-title":"On the Relationship Between VDR, Ror\u03b1 and Ror\u03b3 Receptors Expression and HIF1-\u03b1 Levels in Human Melanomas","volume":"28","author":"Bro\u017cyna","year":"2019","journal-title":"Exp Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.03.031","article-title":"Expression of the Vitamin D-Activating Enzyme 1\u03b1-Hydroxylase (CYP27B1) Decreases During Melanoma Progression","volume":"44","author":"Bro\u017cyna","year":"2013","journal-title":"Hum Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-208975","article-title":"In Vivo Evidence for a Novel Pathway of Vitamin D3 Metabolism Initiated by P450scc and Modified by CYP27B1","volume":"26","author":"Slominski","year":"2012","journal-title":"FASEB J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.12.012","article-title":"In Vivo Production of Novel Vitamin D2 Hydroxy-Derivatives by Human Placentas, Epidermal Keratinocytes, Caco-2 Colon Cells and the Adrenal Gland","volume":"383","author":"Slominski","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111238","article-title":"The Significance of CYP11A1 Expression in Skin Physiology and Pathology","volume":"530","author":"Slominski","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/srep14875","article-title":"Detection of Novel CYP11A1-Derived Secosteroids in the Human Epidermis and Serum and Pig Adrenal Gland","volume":"5","author":"Slominski","year":"2015","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0441","article-title":"Simultaneous Measurement of 13 Circulating Vitamin D3 and D2 Mono and Dihydroxy Metabolites Using Liquid Chromatography Mass Spectrometry","volume":"59","author":"Jenkinson","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.4537","article-title":"Vitamin D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With But Not Without Rituximab","volume":"32","author":"Bittenbring","year":"2014","journal-title":"J Clin Oncol"},{"key":"B30","unstructured":"NICE Guideline [NG14]): Melanoma: Assessment and Management"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.839816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T16:41:15Z","timestamp":1653064875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.839816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.839816"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.839816","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"article-number":"839816"}}